What type of study is this?

This is a Human Clinical Trial study (also classified as: Pre-Registered Trial).

What question did this study set out to answer?

To evaluate the safety and feasibility of CLL-1 CAR T-cells in patients with r/r AML as a step toward HSCT.

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Phase 1 clinical trial demonstrates CLL-1 CAR T-cells improve outcomes in patients with r/r AML, highlighting potential for HSCT.

To evaluate the safety and feasibility of CLL-1 CAR T-cells in patients with r/r AML as a step toward HSCT.
Phase 1 clinical trial involving CLL-1 CAR T-cells generated from autologous PBMCs.
Patient population included those with ≥30% CLL-1 expression on AML blasts; treatment included lymphodepletion.
Patients received escalating doses of CLL-1 CAR T-cells after lymphodepleting chemotherapy.
12 adults and 2 adolescents treated with median age of 46 years, median CLL-1 expression 81%.
CRS occurred in 12/14 patients; one patient developed grade 3 ICANS with other adverse events noted.
Two patients achieved complete response with incomplete recovery; two underwent HSCT, with one alive 2 years post infusion.

Wang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark